Basic | |
---|---|
Market Cap | $1.81M |
Price | $5.3 |
52 Week Range | 0.432-20.16 |
Beta | 0.56 |
Margins | |
Gross Profit Margin | -166659512925868.63% |
Operating Profit Margin | -174757204553831520.00% |
Net Profit Margin | -173257268937499424.00% |
Valuation (TTM) | |
P/E Ratio | -0.17 |
Price to Sales Ratio | 59670281832911.91 |
Price to Book Ratio | -1.50 |
PEG Ratio | 0.18 |
Drug Manufacturers - Specialty & Generic
Healthcare
7
2020-09-01T00:00:00.000Z
PainReform Ltd., a clinical stage specialty pharmaceutical company, engages in the development of therapeutics that provides an extended period of post-surgical pain relief in Israel. It engages in developing PRF-110, a viscous clear oil-based solution that is instilled directly into the surgical wound to provide localized and extended post-operative analgesia. The company is currently conducting two Phase 3 clinical trials of PRF-110 for the treatment of patients undergoing bunionectomy surgery and hernia repair. PainReform Ltd. was incorporated in 2007 and is based in Tel Aviv, Israel.
972 3 717 7050
65 Yigal Alon Street, Tel Aviv, 6745442, IL
0001801834